{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:28:43Z","timestamp":1777386523809,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Rhinology"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rhinorrhea and nasal congestion are simultaneous symptoms associated with the common cold. This study investigated the efficacy and safety of a combination nasal spray of ipratropium and xylometazoline for simultaneous treatment of these symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The trial was a multicenter double-blind, parallel-group, randomized design on patients with common cold symptoms. Patients scored symptoms of runny nose and nasal congestion and recorded adverse events in a diary for up to 7 days. Patients also recorded tissue use. The five test treatments consisted of ipratropium, 0.6 mg\/mL, and xylometazoline, 1.0 mg\/mL; ipratropium, 0.6 mg\/mL, and xylometazoline, 0.5 mg\/mL; ipratropium, 0.6 mg\/mL; xylometazoline, 1.0 mg\/mL; and placebo solution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight hundred sixty-four patients were screened and 786 patients received treatment. One day after treatment there was a clear separation between the scores for the placebo and ipratropium treatment groups for rhinorrhea and between the placebo and xylometazoline treatment groups for congestion. Both ipratropium\/xylometazoline 1.0 and ipratropium\/xylometazoline 0.5 treatments were superior to xylometazoline with respect to rhinorrhea (p &lt; 0.0001) and superior to ipratropium with respect to nasal congestion scores (p &lt; 0.001). Both the ipratropium combination treatments had significantly lower tissue use than the xylometazoline treatment group (p &lt; 0.0001). Adverse events were distributed equally between the treatments, except mucus tinged with blood, epistaxis, nasal passage irritation, and nasal dryness, which had a higher incidence in the three groups that received medicines containing ipratropium.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results indicate that a combination medicine of ipratropium and xylometazoline is safe and effective for treatment of rhinorrhea and nasal congestion associated with common cold.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2500\/ajr.2007.21.2902","type":"journal-article","created":{"date-parts":[[2007,1,28]],"date-time":"2007-01-28T18:20:14Z","timestamp":1170008414000},"page":"40-45","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and Safety of Topical Combinations of Ipratropium and Xylometazoline for the Treatment of Symptoms of Runny Nose and Nasal Congestion associated with Acute Upper Respiratory Tract Infection"],"prefix":"10.1177","volume":"21","author":[{"given":"Ronald","family":"Eccles","sequence":"first","affiliation":[{"name":"Common Cold Centre, Cardiff School of Biosciences, Cardiff University, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Nycomed, Roskilde, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Regberg","sequence":"additional","affiliation":[{"name":"Alviva AB, Brumma, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heikki","family":"Tulento","sequence":"additional","affiliation":[{"name":"Occupational Health Department, Clinic Mehil\u00e4inen, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Borum","sequence":"additional","affiliation":[{"name":"Ear-Nose-Throat Department, K\u00f8ge University Hospital, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4r","family":"Stj\u00e4rne","sequence":"additional","affiliation":[{"name":"Ear, Nose, and Throat Department, Karolinska University Hospital\/Huddinge, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2007,1,1]]},"reference":[{"key":"bibr1-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-7930-0_1"},{"key":"bibr2-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268800056764"},{"key":"bibr3-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4637.2003.03019.x"},{"key":"bibr4-ajr.2007.21.2902","first-page":"418","volume":"123","author":"Borum P.","year":"1981","journal-title":"Am Rev Respir Dis"},{"key":"bibr5-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90126-M"},{"key":"bibr6-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70219-9"},{"key":"bibr7-ajr.2007.21.2902","first-page":"58","volume":"35","author":"Ostberg B.","year":"1997","journal-title":"Rhinology"},{"key":"bibr8-ajr.2007.21.2902","first-page":"109","volume":"10","author":"Hamilton L.H.","year":"1981","journal-title":"J Otolaryngol"},{"key":"bibr9-ajr.2007.21.2902","first-page":"277","volume":"30","author":"Williams R.G.","year":"1992","journal-title":"Rhinology"},{"key":"bibr10-ajr.2007.21.2902","first-page":"27","volume":"28","author":"Castellano F.","year":"2002","journal-title":"Drugs Exp Clin Res"},{"key":"bibr11-ajr.2007.21.2902","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.","year":"2000","journal-title":"In Guidance for Industry"},{"key":"bibr12-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1002\/cpt197721134"},{"key":"bibr13-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3244-0_5"},{"key":"bibr14-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780122404"},{"key":"bibr15-ajr.2007.21.2902","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-2-199607150-00002"}],"container-title":["American Journal of Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/ajr.2007.21.2902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2500\/ajr.2007.21.2902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:36:25Z","timestamp":1777368985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2500\/ajr.2007.21.2902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.2500\/ajr.2007.21.2902"],"URL":"https:\/\/doi.org\/10.2500\/ajr.2007.21.2902","relation":{},"ISSN":["1050-6586","1539-6290"],"issn-type":[{"value":"1050-6586","type":"print"},{"value":"1539-6290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}